Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Harbour BioMed Signs mAb Discovery Deal with Global Top Ten Biopharma

publication date: May 29, 2019

Harbour BioMed has signed a global multi-year license agreement with an unnamed top-ten immunology/immuno-oncology pharma to use Harbour's HCAb transgenic mouse platform to discover, develop and commercialize biologic therapeutics. The HCAb platform generates novel, fully human heavy chain only antibodies. Harbour says the platform will accelerate the discovery and development of single domain antibodies, bi-specific and multi-specific antibodies, and CAR-Ts. Harbour has R&D sites in Shanghai and Suzhou, business and research operations in Boston, and an antibody platform in Rotterdam. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital